drug:wegovy
Wegovy in pill form is coming
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
drug:nimacimab
Boosting Tirzepatide with Nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer
Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
drug:mounjaro
Mounjaro's India launch
Eli Lilly's Mounjaro launches in India
category:news
Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!
politics
Trump revokes planned Medicare/Medicaid coverage for GLP1s
Trump administration revokes the planned Medicare Part D coverage for anti-obesity GLP1 drugs.
politics
2025 Trump Tariffs on Pharmaceutical Imports
Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
Once a year GLP1? Exploring Semaglutide implants
GLP1 implants that are administered once or twice a year and deliver consistent Semaglutide, powered by Vivani Medical's NanoPortal technology.
category:news
Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
research
STRIDE study: GLP1s vs peripheral artery disease (PAD)
Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:news
Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm
Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).